Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975280 | 0.89 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL6979441 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1 | |
| SCHEMBL6976911 | 0.84 | OPRL1 (0.33) | KDM4EOPRL1 | |
| SCHEMBL6959221 | 0.80 | — | — | |
| SCHEMBL6978880 | 0.72 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL15304811 | 0.71 | CYP1A2 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL6959092 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1 | |
| SCHEMBL5012078 | 0.70 | KDM4E (0.39) | KDM4EALDH1A1OPRL1 | |
| SCHEMBL13814700 | 0.70 | — | — | |
| SCHEMBL6976181 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | KDM4E 2805/4885ALDH1A1 4593/4885OPRL1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.